Kazuhiro Asami

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009 · 4.1K citations

Open Label, Medicine, Cancer Growth +10

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 261 citations · Full text

Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study

Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita et al. · Journal of Clinical Oncology · 2010 · 163 citations

Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · Journal of Clinical Oncology · 2012 · 145 citations

Platinum Doublet, Surgical Oncology, Cancer Management +21

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations

Kenichi Nishie, Tomoya Kawaguchi, Akihiro Tamiya et al. · Journal of Thoracic Oncology · 2012 · 107 citations

Activating Egfr Mutations, Medicine, Receptor Tyrosine Kinase +8